121 related articles for article (PubMed ID: 11069388)
1. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer.
Hrouda D; Todryk SM; Perry MJ; Souberbielle BE; Kayaga J; Kirby RS; Dalgleish AG
BJU Int; 2000 Oct; 86(6):742-8. PubMed ID: 11069388
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer.
Hrouda D; Souberbielle BE; Kayaga J; Corbishley CM; Kirby RS; Dalgleish AG
Br J Urol; 1998 Dec; 82(6):870-6. PubMed ID: 9883227
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.
Pandha HS; Cook D; Greenhalgh R; Dalgleish A
BJU Int; 2005 Jun; 95(9):1336-43. PubMed ID: 15892827
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
[TBL] [Abstract][Full Text] [Related]
5. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity.
Todryk SM; Eaton J; Birchall L; Greenhalgh R; Soars D; Dalgleish AG; Melcher AA; Pandha HS
Cancer Immunol Immunother; 2004 Apr; 53(4):323-30. PubMed ID: 14648067
[TBL] [Abstract][Full Text] [Related]
6. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
[TBL] [Abstract][Full Text] [Related]
7. Oral bropirimine immunotherapy of rodent prostate cancer.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine.
Knight BC; Souberbielle BE; Rizzardi GP; Ball SE; Dalgleish AG
Melanoma Res; 1996 Aug; 6(4):299-306. PubMed ID: 8873049
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).
Hrouda D; Baban B; Dunsmuir WD; Kirby RS; Dalgleish AG
Br J Urol; 1998 Oct; 82(4):568-73. PubMed ID: 9806190
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
[TBL] [Abstract][Full Text] [Related]
13. PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Suckow MA; Wheeler J; Yan M
Can J Vet Res; 2009 Jan; 73(1):39-41. PubMed ID: 19337394
[TBL] [Abstract][Full Text] [Related]
14. A novel murine model of allogeneic vaccination against prostate cancer.
Labarthe MC; Theocharous P; Russell N; Todryk S; Bangma C; Thraves P; Dalgleish AG; Whelan MA
Cancer Immunol Immunother; 2008 Apr; 57(4):453-65. PubMed ID: 17805533
[TBL] [Abstract][Full Text] [Related]
15. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a tissue vaccine enhances the effect of irradiation on prostate tumors.
Suckow MA; Wheeler J; Wolter WR; Sailes V; Yan M
In Vivo; 2008; 22(2):171-7. PubMed ID: 18468400
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of prostate cancer metastasis by administration of a tissue vaccine.
Suckow MA; Wolter WR; Sailes VT
Clin Exp Metastasis; 2008; 25(8):913-8. PubMed ID: 18821060
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.
Pienta KJ; Naik H; Akhtar A; Yamazaki K; Replogle TS; Lehr J; Donat TL; Tait L; Hogan V; Raz A
J Natl Cancer Inst; 1995 Mar; 87(5):348-53. PubMed ID: 7853416
[TBL] [Abstract][Full Text] [Related]
19. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
Oades GM; Dredge K; Kirby RS; Colston KW
BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
